This study aims to see if a new treatment combination, Xaluritamig plus Abiraterone, helps patients with metastatic castration-resistant prostate cancer (mCRPC) live longer than current treatments like Docetaxel, Cabazitaxel, or Abiraterone. Metastatic means the cancer has spread from the original site, and castration-resistant means the cancer continues to grow even after treatments that lower testosterone.

To participate, you must be 18 or older, have prostate cancer that has spread, and have tried one other treatment without success. You cannot join if your cancer has spread to your brain or if you've had certain other treatments recently.

• This study compares two treatment groups and requires prior consent.
• Participants must have previously undergone specific treatments and procedures.
• There are several exclusions based on prior treatments and current health status.

Be aware that this study involves specific eligibility requirements and previous treatments. Participants will be monitored for their health and response to the treatment. It's important to discuss with your doctor if this study is right for you.